Clinical Endocrinology · 1988 · 58 citations · 5 references
MedicineEndocrinologyPharmacologyClinical PharmacologyNeuropharmacologyPharmacodynamicsDopaminergic PharmacologyGrowth DisordersGrowth HormoneGrowth Hormone RegulationGrowth Hormone TherapyBromocriptine TreatmentCabergoline TreatmentProlactin Levels MonitoringSingle-dose Administration
Cabergoline, the new long-acting dopaminergic ergoline derivative, was given orally in single doses of 0.3 and 0.6 mg to eight dopamine-responsive acromegalic patients. Serum GH and PRL levels were determined before treatment, 3, 4, and 6 h and 1, 3, 5, 7 and 14 days after treatment. A control test with a single oral dose of 2.5 mg of bromocriptine was also performed. Cabergoline induced a marked fall in serum PRL level, starting within 3 h and continuing for 7 days after administering 0.3 mg, and for 14 days after 0.6 mg. The mean maximal decrease was 49% after 0.3 mg and 63% after 0.6 mg and occurred after 24 h in both cases. The latter was of similar magnitude to that induced by bromocriptine (67% at 4 h). Serum GH levels did not change after 0.3 mg of cabergoline, but decreased significantly from 3 h to 3 days after 0.6 mg of the compound with a mean maximal decrease of 42% after 24 h, and from 3 to 6 h after giving bromocriptine (mean maximal decrease 63% at 4 h). Once a week repeated administration of 0.3-0.6 mg of cabergoline was carried out in six patients, five of whom had completed the acute study; a normalization of serum GH and insulin-like growth factor I (IGF-I) levels occurred in three patients, one of whom had very high pretreatment values. In three poorly or nonresponsive patients, a better response, as assessed by both GH and IGF-I levels, was induced by increasing the dose up to 0.6 mg twice or 0.4 mg three times a week; in one case this was associated with marked tumour shrinkage. Sustained normalization of PRL levels was achieved in all cases. These data indicate that a single dose of 0.6 mg of cabergoline inhibits GH as well as PRL secretion in dopamine-responsive acromegalic patients and suggests that doses of 0.3-0.6 mg once to three times a week may prove suitable for treatment of this condition.
5
The Two-Period Change-Over Design and Its Use in Clinical Trials
James E. Grizzle · Biometrics · 1965 · 788 citations
William H. Daughaday, Ida K. Mariz, Sandra L. Blethen · The Journal of Clinical Endocrinology & Metabolism · 1980 · 745 citations
A. E. Pontiroli, Gc Viberti, Ruggero Mangili et al. · British Journal of Clinical Pharmacology · 1987 · 32 citations · Full text